DiveWire guarantees visibility for your news announcements through instant distribution to BioPharma Dive’s audience and its 153,500 newsletter subscribers for 21 days.

IBS has classically been regarded as a “diagnosis of exclusion,” but new research suggested that might be changing with better diagnostic and treatment approaches.